View ValuationCentral Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Central Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026お知らせ • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladeshお知らせ • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025お知らせ • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladeshお知らせ • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.お知らせ • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).お知らせ • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.お知らせ • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Central Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:CENTRALPHL - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202534-1900N/A9/30/202534-2900N/A6/30/202533-22-1-1N/A12/31/2024-28-4422N/A9/30/20247-3822N/A6/30/202430-4233N/A3/31/2024112-5900N/A12/31/202390-4600N/A9/30/202354-4100N/A6/30/202329-4400N/A9/30/202225-68-1-1N/A6/30/202226-68-1-1N/A6/30/2021148-8-52N/A6/30/2020140-1,10700N/A3/31/2020173-545-42N/A12/31/201920617-74N/A9/30/201923430N/A8N/A6/30/201930757N/A10N/A3/31/201935583N/A35N/A9/30/201837181N/A30N/A6/30/201832061N/A29N/A3/31/201827229N/A8N/A9/30/2017473112N/A21N/A6/30/2017456109N/A20N/A3/31/2017485133N/A7N/A12/31/2016440116N/A2N/A9/30/201634881N/A-2N/A6/30/201641798N/A-1N/A3/31/2016477100N/A69N/A12/31/2015553122N/A83N/A9/30/2015624135N/A145N/A6/30/2015661143N/A141N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CENTRALPHLの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CENTRALPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CENTRALPHLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CENTRALPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CENTRALPHLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CENTRALPHLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 07:18終値2026/06/09 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Central Pharmaceuticals Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026
お知らせ • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025
お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladesh
お知らせ • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025
お知らせ • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladesh
お知らせ • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024
New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).
Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
お知らせ • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024
Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).
お知らせ • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023
お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.
お知らせ • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023
New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).
New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).
Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.
Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.